AFP and hepatocellular carcinoma: Pooling the patient-level efficacy data of the Japanese REACH-2 subpopulation and the Japanese REACH subpopulation with baseline AFP ≥ 400 ng/mL provided a larger patient population (N = 101); the pooled efficacy analyses also showed a survival benefit for ramucirumab in Japanese patients with HCC.